✦ LIBER ✦

Interferon adjuvant therapy of melanoma

✍ Scribed by John M. Kirkwood; David Wazer; Maury Rosenstein

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 58 KB
Volume: 79
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19970501)79:9<1843::aid-cncr33>3.0.co;2-w

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

✍ Larry Nathanson 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 344 KB 👁 1 views

Formation of neutralizing antibodies aga

Formation of neutralizing antibodies against natural interferon-β, but not against recombinant interferon-γ during adjuvant therapy for high-risk malignant melanoma patients

✍ R. Dummer; W. Müller; F. Nestle; J. Wiede; J. Dues; W. Lechner; I. Haubitz; W. W 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB

Postsurgical adjuvant therapy for melano

Postsurgical adjuvant therapy for melanoma : Evaluation of a 3-year randomized trial with recombinant interferon-α after 3 and 5 years of follow-up

✍ Luigi Rusciani; Sandra Petraglia; Massimo Alotto; Stefano Calvieri; Giampaolo Ve 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

patients with melanoma. The results obtained with medical therapies are still quite disappointing, with better results observed in soft tissue and lymph node

Adjuvant therapy of melanoma with interf

Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes : Gabapentin may serve as a mood stabilizer

✍ Donna B. Greenberg; Eric Jonasch; Michele A. Gadd; Bonita F. Ryan; James R. Ever 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## BACKGROUND. The use of a high dose regimen of interferon-alpha-2b (IFN) has recently been demonstrated to benefit patients with resected high risk melanoma. The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common. IFN has been associated with nu

Adjuvant therapy of melanoma

✍ Sanjiv S. Agarwala; John M. Kirkwood 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views

Patients with AJCC Stage IIB and III melanoma have a poor 5-year survival rate which has been the driving force behind attempts to find an effective adjuvant therapy for this stage of disease that would effectively reduce relapse and improve survival. Immunotherapy with bacillus Calmette-Guerin (BCG

Intralesional interferon-alpha therapy i

Intralesional interferon-alpha therapy in advanced malignant melanoma

✍ Peter Von Wussow; Berthold Block; F. Hartmann; Helmuth Deicher 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB 👁 2 views